Cocrystal Pharma Files 8-K
Ticker: COCP · Form: 8-K · Filed: Jul 18, 2024 · CIK: 1412486
| Field | Detail |
|---|---|
| Company | Cocrystal Pharma, INC. (COCP) |
| Form Type | 8-K |
| Filed Date | Jul 18, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, filing
TL;DR
Cocrystal Pharma filed an 8-K on July 18, 2024. Details pending.
AI Summary
On July 18, 2024, Cocrystal Pharma, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific material events or financial figures were detailed in the provided excerpt.
Why It Matters
This filing indicates Cocrystal Pharma, Inc. is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for disclosures and exhibits, with no immediate indication of significant negative events.
Key Players & Entities
- Cocrystal Pharma, Inc. (company) — Registrant
- July 18, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38418 (identifier) — Commission File Number
- 35-2528215 (identifier) — IRS Employer Identification No.
- 19805 N. Creek Parkway (address) — Principal executive offices
- Bothell, WA (location) — Principal executive offices location
- 98011 (zip_code) — Principal executive offices zip code
- (877) 262- (phone_number) — Registrant's telephone number
FAQ
What specific information is being disclosed under Regulation FD?
The provided excerpt does not detail the specific content of the Regulation FD disclosure.
What financial statements or exhibits are included in this filing?
The excerpt indicates that financial statements and exhibits are included, but their specific contents are not listed.
Has Cocrystal Pharma, Inc. undergone any recent name changes?
The filing notes former company names 'BIOZONE PHARMACEUTICALS, INC.' (changed March 4, 2011) and 'International Surf Resorts, Inc.' (changed September 17, 2007), but no recent changes are indicated.
What is the primary business of Cocrystal Pharma, Inc. according to the filing?
Cocrystal Pharma, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Where are Cocrystal Pharma, Inc.'s principal executive offices located?
The principal executive offices are located at 19805 N. Creek Parkway, Bothell, WA 98011.
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-07-18 09:00:13
Filing Documents
- form8-k.htm (8-K) — 38KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001493152-24-028283.txt ( ) — 234KB
- cocp-20240718.xsd (EX-101.SCH) — 3KB
- cocp-20240718_lab.xml (EX-101.LAB) — 33KB
- cocp-20240718_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: July 18, 2024 Cocrystal Pharma, Inc. By: /s/ James Martin Name: James Martin Title: Chief Financial Officer and Co-Chief Executive Officer